Skip to main content

Longwood Fund — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

56
Companies
$4.3B
Total invested
$77.3M
Avg. check
17
Industries
Biotechnology 22Health Care 13Therapeutics 12Pharmaceutical 9Life Science 8Biopharma 7+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 56
Khartis Therapeutics
August 2026

Khartis is a drug discovery company developing oral therapies for immune-mediated and chronic diseases, with a focus on treatments and care.

Biopharma · San Diego$50.0M Series B
Coultreon Biopharma
April 2026

CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.

Analytics · Heverlee$125.0M Series A
Neomorph
April 2026

Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.

Biotechnology · San Diego$100.0M Series B
Sidewinder Therapeutics
April 2026

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

Biotechnology · San Diego$137.0M Series B
Evommune
February 2026

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Biotechnology · Palo Alto$125.0M Post-IPO Equity
AAVantgarde Bio
November 2025

AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.

Biotechnology · Milano$141.0M Series B
Vertero
October 2025

Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.

Biopharma · Woburn$20.0M Series D
KalVista Pharmaceuticals
September 2025

KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.

Biopharma · Cambridge$125.0M Post-IPO Debt
Avenzo Therapeutics
September 2025

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

Biotechnology · San Diego$60.0M Series B
Solu Therapeutics
April 2025

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

Biotechnology · Boston$41.0M Series A
Newleos Therapeutics
February 2025

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Biotechnology · Boston$93.5M Series A
Be Biopharma
January 2025

Be Biopharma develops engineered B cell medicines for serious genetic diseases.

Biopharma · Cambridge$92.0M Series C
XyloCor Therapeutics
January 2025

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

Biotechnology · King Of Prussia$67.5M Series B
TScan Therapeutics
December 2024

TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.

Biotechnology · Waltham$30.0M Post-IPO Equity
Interius BioTherapeutics
June 2024

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.

Biopharma · Philadelphia$51.4M Series B
Progentos Therapeutics
May 2024

Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Life Science · Watertown$65.0M Series A
BBOT
May 2024

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.

Biopharma · Palo Alto$200.0M Venture - Series Unknown
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Tome Biosciences
December 2023

Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.

Biotechnology · Watertown$213.0M Series A
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
Pulmocide
December 2022

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Biotechnology · London$52.0M Series C
Photys Therapeutics
September 2022

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Biotechnology · Cambridge$75.0M Series A
DEM BioPharma
June 2022

DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.

Biotechnology · Cambridge$70.0M Series A
Carbon Biosciences
June 2022

Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.

Biotechnology · Lexington$38.0M Series A

Where Longwood Fund invests

Biotechnology22
Health Care13
Therapeutics12
Pharmaceutical9
Life Science8
Biopharma7

About Longwood Fund's portfolio

How many companies has Longwood Fund invested in?▸

Longwood Fund has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Longwood Fund invest in?▸

Longwood Fund's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Life Science. The firm invests across 17 different industry categories.

What is Longwood Fund's largest investment?▸

Among tracked funding rounds, Tome Biosciences received $213.0M in a Series A round. Longwood Fund's total known invested capital is $4.3B.

What is the average investment size for Longwood Fund?▸

Longwood Fund's average investment size is $77.3M across its portfolio of 56 companies.

What are Longwood Fund's most recent investments?▸

Recent Longwood Fund portfolio additions include Khartis Therapeutics, Coultreon Biopharma, Neomorph, Sidewinder Therapeutics, Evommune. These companies were founded in 2020 or later.

Reach the founders behind these 56 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →